Investors pile onto TenNor IPO with hopes for new type of gastric drug
The biotech enjoyed a standout Hong Kong share debut after hailing its novel anti-bacterial drug, now undergoing late-stage clinical tests, as a potential gamechanger Key Takeaways: The TenNor Therapeutics IPO…
RELATED ARTICLES
-
Precision-drug maker Impact Therapeutics ignites IPO frenzy
- Hong Kong to welcome world-leading siRNA company as Ribo launches its IPO
- BRIEF: Heavily oversubscribed TenNor Therapeutics soars in trading debut
- Geneplus locks onto targeted medicine for IPO pitch
- Eye drug maker VivaVision feels the strain in IPO funding dash
- A healthy return: drug spin-off nets Keymed up to $320 million
- Jacobio Pharma poised to turn a profit from precision cancer drugs
